

PRESS RELEASE | LYON, FRANCE – April 3rd 2026

SEQENS to launch PeptiCode™ HP-9: the first European biotech Hexapeptide-9

SEQENS is dedicated to offering sustainable and advanced cosmetic solutions to shape the future of personal care with its customers and partners.

The group is set to launch **PeptiCode™ HP-9, the first European biotech Hexapeptide-9**, developed through the PeptiCode™ **biotechnology platform** based in Nîmes, France. This platform specializes in various microorganisms' optimization – such as bacteria, yeast, and microalgae – through strain engineering and fermentation technologies to unlock access to sustainable and innovative naturally-derived peptides.

PeptiCode™ HP-9 is created via **precision fermentation**, harnessing the power of an optimised microorganism **to synthesise a pure, 100% natural origin and bio-identical hexapeptide-9**. SEQENS' process complies with the principles of Green Engineering and ensures high performance and optimal peptide stability **without using TFA** (trifluoroacetic acid) or **PFAS** (per- and polyfluoroalkyl substances) during production.

This versatile product is designed for **new sustainable anti-aging formulations**, as it acts as a signal peptide to **boost collagen synthesis**. Easy to use and interchangeable with its synthetic counterpart, PeptiCode™ HP-9 is a drop-in replacement. It offers the advantage of avoiding chemical synthesis, while guaranteeing a high-performance, environmentally friendly product.

SEQENS will exhibit at inCosmetics Global 2026 in Paris. Visit us at stand #3Q48 to discover PeptiCode™ HP-9 and the PeptiCode™ platform, designed to develop innovative peptides that contribute to a more sustainable, biotechnology-focused future, meeting the needs of next-generation beauty and personal care products.

In case you want to learn more about other products from SEQENS, please feel free to get in contact with us at press@seqens.com.

About SEQENS:

SEQENS is a global partner in health and specialty ingredients serving a wide range of demanding markets, including personal care, pharmaceuticals and healthcare and other high-performance industries such as specialty chemicals.

With a constant concern for sustainability, we empower innovation to bring the best solutions to our customers and meet the expectations of our customers. Relying on the skills of 2,700 employees, we leverage a worldwide manufacturing network of 15 sites, and 5 state-of-the-art R&D centers.

Learn more: press@seqens.com / www.seqens.com / LinkedIn: [SEQENS](https://www.linkedin.com/company/seqens)